Trends in mortality burden of hepatocellular carcinoma, cirrhosis, and fulminant hepatitis before and after roll-out of the first pilot vaccination program against hepatitis B in Peru: An analysis of death certificate data

Ramírez-Soto, Max Carlos; Ortega-Cáceres, Gutia; Cabezas, César

doi:10.1016/j.vaccine.2017.05.086

Cited by 13 publications

(14 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our findings also showed a reduction in HBsAg rates, indicating a low endemicity level, in the previously hyperendemic areas of the Peruvian Amazon and the inter-Andean valleys of the highlands (Ayacucho and Apurímac). These findings are compatible with the impact of the vaccination program against HBV that the MINSA (Ministry of Health, Peru) launched in 1991-1994 in the inter-Andean valleys of the Peruvian highlands (Abancay and Huanta), followed in 1996 by the implementation of vaccination for children aged under 1 year living in intermediate-and high-endemic areas and then in 2003 with universal vaccination for all children aged under 1 year in Peru [15,24]. Changes in endemicity levels from high or intermediate to low as a result of universal vaccination against HBV have also been reported in countries, including China, Italy, Australia, Gambia and Colombia [25].…”

Section: Plos Onesupporting

confidence: 81%

“…In Peru, a pilot vaccination program against hepatitis B was introduced in two hyperendemic provinces (Abancay and Huanta) in 1991 and 1994 for children aged under 5 years, and it was extended in 2003 to include all newborns in HBV-endemic areas. As a result of this intervention, several advances have been made in the control of HBV infection over the last 20 years, including reduced mortality burden from liver diseases associated with HBV infection such as cirrhosis, hepatocellular carcinoma and fulminant hepatitis [15]. According to data from a serological survey in the Peruvian Amazon, the prevalence of HBsAg in children aged under 5 years fell to zero in 2010 [16], and the prevalence of HBsAg in the general population of the highlands decreased from 9.8% to <2% after 20 years of the vaccination program [15].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Seroepidemiology of hepatitis A, B, C, D and E virus infections in the general population of Peru: A cross-sectional study

et al. 2020

Self Cite

View full text Add to dashboard Cite

Background Viral hepatitis (hepatitis A, B, C, D and E) remains a public health problem in Peru, with a high disease burden. There are limited data on the prevalence of viral hepatitis at a national level, and none reported for over two decades. In this study, the prevalence rates of hepatitis A (HAV), B (HBV), C (HCV), D (HDV) and E virus (HEV) infections in the Peruvian population were determined to provide updated baseline data that would help guide the development of strategies aimed at reducing the transmission of viral hepatitis in Peru. Methods We conducted a cross-sectional, population-based study in the 25 regions of Peru. The study included participants of both sexes, aged 15-69 years, who had lived for >6 months in a specific region of Peru. Serum samples were analyzed by ELISA for anti-HAV (IgG), anti-HBs �10 mUI/ml, anti-HCV, anti-HDV and anti-HEV (IgG) antibodies, and by chemiluminescence for the HBV surface antigen (HBsAg) and antibodies against the core HBV antigen (anti-HBc IgM and IgG). Results In a total of 5183 study participants, the prevalence rates of anti-HAV (IgG), HBsAg, total anti-HBc IgG, anti-HBs �10 mUI/ml, anti-HCV and anti-HEV (IgG) were 98.4% [95% confidence interval (CI) 98.0-98.7), 0.4% (95% CI 0.21-0.55), 10.1% (95% CI 9.4-11.0), 60% (95% CI 58.5-61.2), 0.1% (95% CI 0.02-0.25), and 14% (95% CI 13.1-15.0%), respectively. The prevalence of anti-HDV among HBsAg carriers was 15% (3/20).

show abstract

Section: Plos Onesupporting

confidence: 81%

Section: Introductionmentioning

confidence: 99%

Seroepidemiology of hepatitis A, B, C, D and E virus infections in the general population of Peru: A cross-sectional study

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…Según nuestros hallazgos, encontramos mayor mortalidad por fibrosis y cirrosis del hígado en la costa norte (Piura, Lambayeque y La Libertad), a diferencia del período 1995-2000, en el que la cirrosis hepática tuvo altas tasas de mortalidad en la sierra, principalmente en Cusco, en asociación con hepatitis viral B 3 ; es probable que la disminución de la mortalidad en algunas regiones de la sierra se deba a la vacunación contra este virus 22 . El descenso de las tasas a nivel internacional se ha relacionado a varios factores, entre ellos las mejoras en el tratamiento de la cirrosis y sus complicaciones, así como la disminución en la prevalencia de hepatitis viral B y C 15 .…”

Section: Discussionunclassified

Mortalidad por enfermedades digestivas no neoplásicas en la población adulta del Perú, 2010 – 2015

Castillo-Contreras

Flores-Flores

2019

An Fac med

View full text Add to dashboard Cite

Introducción. Las enfermedades digestivas (ED) no neoplásicas son causas importantes de consulta médica y hospitalización. Objetivo. Determinar la mortalidad por ED no neoplásicas en la población adulta del Perú entre 2010 y 2015. Métodos. Análisis secundario del registro de defunciones por ED no neoplásicas en la población mayor de 18 años entre los años 2010 y 2015 de la Oficina General de Estadística e Informática del Ministerio de Salud del Perú. La población para el mismo periodo se obtuvo del Instituto Nacional de Estadística e Informática. Se calcularon las tasas de mortalidad estandarizada (TME x 100 000 personasaño). Resultados. Durante el período 2010-2015 se registraron 39 889 muertes por ED no neoplásicas. Las TME más altas fueron para el grupo de las enfermedades del hígado (12,2 x 100 000 personas-años), siendo la fibrosis y cirrosis del hígado la de mayor mortalidad (9,1). La pancreatitis aguda (1,0) tuvo mayor TME que la úlcera gástrica (0,7). Las TME, según las regiones del Perú, fueron altas por fibrosis y cirrosis del hígado en Piura (16,3), Lambayeque (14,6) y La Libertad (14,4); por colelitiasis (1,1) y colecistitis aguda (1,7), en Puno; por pancreatitis aguda (2,2), en Tacna; y por úlcera gástrica fue mayor en Huancavelica (3,6) y Huánuco (2,3). Conclusiones. La fibrosis y cirrosis del hígado fue la ED no neoplásica con mayor tasa de mortalidad en la población adulta del Perú, principalmente en la costa norte del país.

show abstract

“…In Peru, South Africa, and many Asian countries, the introduction of hepatitis B vaccination programs has caused a decrease in the incidence of pediatric HCC . Globally, HCC, including its rare histologically distinct variant fibrolamellar hepatocellular carcinoma (FL‐HCC), occurs mostly in older children and adolescents .…”

Section: Epidemiology and Etiologymentioning

confidence: 99%

Is hepatocellular carcinoma the same disease in children and adults? Comparison of histology, molecular background, and treatment in pediatric and adult patients

Weeda

Aronson

Verheij

et al. 2018

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Pediatric hepatocellular carcinoma (HCC) is rare, resulting in scattered knowledge of tumor biology and molecular background. Thus far, the variant in children has been treated as a different entity from adult HCC. We weigh the hypothesis that HCC in the pediatric and adult groups may be the same entity and may benefit from the same treatment. Although certain differences between adult and pediatric HCC are obvious and certain types of HCC may ask for a customized approach, in conventional HCC, similarities predominate, warranting treatment aiming at common molecular targets in adult and pediatric HCC patients.

show abstract

Trends in mortality burden of hepatocellular carcinoma, cirrhosis, and fulminant hepatitis before and after roll-out of the first pilot vaccination program against hepatitis B in Peru: An analysis of death certificate data

Cited by 13 publications

References 15 publications

Seroepidemiology of hepatitis A, B, C, D and E virus infections in the general population of Peru: A cross-sectional study

Seroepidemiology of hepatitis A, B, C, D and E virus infections in the general population of Peru: A cross-sectional study

Mortalidad por enfermedades digestivas no neoplásicas en la población adulta del Perú, 2010 – 2015

Is hepatocellular carcinoma the same disease in children and adults? Comparison of histology, molecular background, and treatment in pediatric and adult patients

Contact Info

Product

Resources

About